Guideline / position statementindependent cross-checkabstract only checked I-INTC-04 standard review
International guideline on lupus kidney disease
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
Overview
Rovin BH et al.. Kidney Int 2024 · PMID 38182299 · DOI 10.1016/j.kint.2023.09.001
Kidney involvement in lupus is treated with specific medicines; the guideline was updated in 2024 after two new drugs were approved.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Summarise the 2024 KDIGO update
- How was the study done?
Guideline executive summary
- How many people, animals or samples were studied?
not applicable
- What was actually found?
Two new drugs led to an update
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Lupus affecting the kidneys needs medical treatment.
- What are the study's limitations?
Abstract only
- What does it say about Elawady's specific claim?
Contradicts the idea that stopping eggs replaces treatment
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Details of recommended regimens (not read)
Scientific in-depth review
1. Full reference
- Authors
- Rovin BH et al.
- Journal
- Kidney Int
- Year
- 2024
- Identifier
- PMID 38182299 DOI 10.1016/j.kint.2023.09.001
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract (PubMed lists non-US government support)
2. Research question
What are the most important changes in the KDIGO guideline for lupus nephritis?
3. Study design and population
- Study design
- Guideline / position statement – Executive summary of an international clinical practice guideline update (KDIGO)
- Population
Patients with lupus nephritis
- Country
International
- Period
2024 update
- Sample size
not applicable
- Inclusion and exclusion criteria
not applicable
4. Methods and endpoints
- Exposure / intervention
Drug treatment of lupus nephritis
- Comparator
not applicable
- Endpoints
Kidney outcomes
- Statistical methods
not reported in abstract
5. Actual results
- Results
Abstract: the 2021 KDIGO glomerular diseases guideline was updated because two novel drugs received regulatory approval for the management of lupus nephritis; the executive summary lists the most important changes of the lupus nephritis chapter.
- Absolute risks
not reported
- Authors' conclusion
Lupus nephritis is managed with specific drug therapies, updated as new drugs are approved.
6. Strengths
- International guideline body (KDIGO)
7. Weaknesses
- Only the abstract was read; recommendations themselves not audited
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline summary; not formally appraised.
9. Assessment of the statistical interpretation
No numbers used.
10. Relevance to the specific claim
Shows that lupus nephritis is treated with approved drug therapies under specialist care; nothing in the abstract suggests diet (e.g. egg avoidance) as a treatment.
11. Independent contrary findings
None found.
12. Transferability to Germany and Europe
KDIGO guidelines are used in Europe and Egypt.
13. Overall methodological judgement
Context source for the standard of care in lupus nephritis.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Detailed regimens were not audited.